Biomarkers, Effectiveness, and Safety of Aflibercept 8mg Modified Fixed Dose Regimen in Treatment-Naïve nAMD Patients

NCT07728981 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

NOT_YET_RECRUITING

Status

49

Enrollment

OTHER

Sponsor class

Conditions

Neovascular Age-Related Macular Degeneration (nAMD) Wet AMD

Interventions

DRUG: Aflibercept 8mg

Sponsor

Tianjin Medical University Eye Hospital

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]